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Abstract 
There is growing interest in the role of the gut microbiome in human health and disease. 
This unique complex ecosystem has been implicated in a number of health conditions 
including intestinal disorders, inflammatory skin diseases and metabolic syndrome. 
However, there is still much to learn regarding its capacity to affect host health. Many 
gut microbiome research studies focus on compositional analysis to better understand 
the causal relationships between microbial communities and disease phenotypes. Yet 
microbial diversity and complexity is such, that community structure alone does not 
provide full understanding of microbial function.  
Metabolic phenotyping is an exciting field in systems biology that provides information 
on metabolic outputs taking place in the system at a given moment in time. These 
readouts provide information relating to by-products of endogenous metabolic 
pathways, exogenous signals arising from diet, drugs and other lifestyle and 
environmental stimuli, as well as products of microbe-host co-metabolism. Thus, better 
understanding of the gut microbiome and host metabolic interplay can be gleaned by 
using such analytical approaches. 
In this Review, we describe research findings focussed on gut microbiota-host 
interactions, for functional insight into the impact of microbiome composition on host 
health. We evaluate different analytical approaches for capturing metabolic activity, 
and discuss analytical methodological advancements that have made a contribution 
to the field. This information will aid in developing novel approaches to improve host 
health in the future, and therapeutic modulation of the microbiome may soon augment 
conventional clinical strategies. 
 2 
Abbreviations 
GC: Gas Chromatography 
1H-NMR: Proton Nuclear Magnetic Resonance 
IBD: Inflammatory Bowel Disease 
IBS: Irritable Bowel Syndrome 
LC: Liquid Chromatography 
MCFA: Medium Chain Fatty Acid 
MRM: Multiple Reaction Monitoring 
MS: Mass Spectrometry 
SCFA: Short Chain Fatty Acid 
 
The human gut contains the most metabolically active microbial community in the 
human body, providing innumerable benefits to host health. Humans depend on gut 
microorganisms for the digestion of complex carbohydrates and fermentation of 
resistant starch plant polysaccharides. These include cellulose, xylans and inulin, 
which are fermented to yield short chain fatty acids (SCFAs) as well as energy. The 
role of the microbiome is often attributed to the digestion of food and extraction of 
nutrients. However, it is also linked to hormone regulation, behavioural activity (1-3), 
and immune system functions (to up to 70%) (4). Many beneficial effects of the gut 
microbiome such as immune homeostasis and host protection from pathogens, are 
exerted through the interplay between gut and host metabolism. Studies in germ-free 
rats have shown decreases in intestinal levels of SCFAs (5), demonstrating the 
importance of the microbiota in energy metabolism. Furthermore, host metabolic 
activities that are inter-twined with the gut can be affected by disease state, lifestyle, 
age and diet; as evidenced in metabolic syndrome (6) Inflammatory Bowel Disease 
(IBD) (7) and liver disease (8). Unravelling the close interplay between host and its 
tiny intestinal residents, will be invaluable in developing and shaping our 
understanding of the many facets of the microbiome, and its role in host health.  
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In recent years, the extent to which host and microbial metabolism are associated has 
been studied extensively. Bi-directional interaction between the two begins at birth (9) 
with the immediate shaping of the immune system (10). Experiments in germ-free mice 
have demonstrated the devastating effects of birth with no immediate microbial 
colonisation, and highlights the importance of a symbiotic relationship (11). Different 
gut populations exist in different regions of the large intestine, and therefore chemical 
cross talk between the host and gut varies. Unique signalling of low molecular weight 
metabolites from the gut to different regions of the body take place via multi-directional 
communication highways, including gut-brain, gut-lung and gut-skin axes (12-14). 
Furthermore, disruption of this metabolic conversation and mutualistic relationship (a 
state termed dysbiosis) has been used to explain the rise in several health conditions 
such as obesity, type 2 diabetes, asthma, IBD, liver disease and cancer (15, 16).  
SCFAs (primarily, butyrate, acetate and propionate) have been demonstrated to be 
extremely important in maintaining colonic health. Butyrate is the preferred energy 
source for colonocytes, with published literature providing evidence that an increase 
in butyrate absorption in the gut can decrease the risk of cancer development through 
stimulation of intestinal epithelial goblet cells (by increased transcription of mucin 
glycoprotein genes), thereby strengthening the colonic defence barrier (17). 
Additionally, these metabolites exhibit anti-inflammatory effects and have been shown 
to regulate the movement and function of neutrophils. For example, butyrate has been 
shown to inhibit growth of pathogenic species of bacteria by reducing the pH (18), 
acetate in the stimulation of peristaltic activity and intestinal motility, whilst propionate 
has been reported to hold antimicrobial properties (19).  
Further experiments focussing on functional assessment of the microbiome can build 
on this knowledge and better understand the implication of changes in bacterial 
composition on host health (20, 21).  This information can potentially be used to treat 
disease in the future, through therapeutic modulation of the microbiota (22, 23).  
Metabolic Phenotyping  
Metabolic phenotyping is an established top-down systems approach for high-
throughput detection and quantification of low molecular weight molecules present in 
body fluids (such as urine and blood plasma/serum), stool and tissues (e.g. biopsies) 
(24, 25) at any given moment in time. This system-wide molecular characterisation 
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enables discrimination between healthy and diseased individuals based on differences 
in metabolic phenotype (26). Metabolites detected include small, intermediate and end 
by-products of endogenous metabolic pathways, but also, products of microbe-host 
co-metabolism (e.g. SCFAs), and exogenous signals arising from diet, drugs and other 
lifestyle and environmental stimuli (27). Capturing changes in bacterially-produced 
metabolites and other microbial co-metabolites following these and other exposures 
such as environmental stresses, antibiotics and pre-, pro- and symbiotic intake (22), 
provides functional insight into the impact of microbiome composition on host health 
(28). Thus, the approach is ideally suited for better understanding the gut microbiome 
and host metabolic interplay, augmenting and complementing information obtained 
from metataxonomics and metagenomics, to gain deeper insight into microbiome 
function (29, 30).  
The major analytical platforms used in metabolic phenotyping are 1H-Nuclear 
Magnetic Resonance (1H-NMR) Spectroscopy (31) and Mass Spectrometry (MS). MS 
can be hyphenated with chromatographic separation techniques such as Gas 
Chromatography (GC) and Liquid Chromatography (LC) for prior separation of 
molecules followed by detection. Samples can also be analysed directly using direct 
infusion (for biofluids) or imaging (for tissues) MS techniques (32). NMR and MS 
analytical technologies enable simultaneous capture of information on hundreds or 
thousands of metabolites from a single biological sample. Urine and faecal samples 
mostly contain information on metabolic end products (including those produced from 
bacteria), whereas blood serum and plasma provide information on circulating 
metabolites. Acquired spectral data captures presence or absence of these low 
molecular weight molecules, as well as metabolite concentration (which can be over 
a wide range within a sample, especially in diseased states where there may be 
additional chemical signals at high intensity due to pathophysiology, or from 
therapeutic intervention (e.g. drugs or diet). Thus, experimental design and selection 
of the most appropriate analytical strategy is essential for optimal information recovery 
(33, 34). Indeed, there are a growing number of studies utilising a multi-platform 
approach for more comprehensive characterisation of metabolic phenotype (35, 36). 
Analysis of this data enables a holistic insight into systems-level processes, and better 
understanding of physiological and pathophysiological disease mechanisms. In 
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particular, identification of metabolites produced as a result of microbial-mammalian 
co-metabolism furthers understanding of host-gut interactions (37, 38).  
Untargeted Metabolic Phenotyping  
Untargeted metabolic phenotyping is often initially used in metabonomics and 
metabolomics studies, as a “hypothesis generating” approach. This analytical strategy 
using NMR and/or MS technologies, does not pre-select compounds to be detected, 
in order to capture unspecified, untargeted spectral profiles (or fingerprints) containing 
information on all the metabolites detectable by the respective analytical platform (31, 
39). The benefit of using an untargeted approach, is that it has the potential to uncover 
novel information which may have been outside the limits of targeted analysis, 
identifying prospective diagnostic and/or prognostic biomarkers of disease (40, 41), 
and molecular mechanisms arising as a result of gut-host interactions (42). Table 1 
summarises a selection of research studies using an untargeted metabolic 
phenotyping approach, that have contributed to the understanding of metabolic cross 
talk between gut microbes and the host, in a variety of health conditions and disease 
states.  
Study  Analytical 
Approach  
Study Results/Key 
Findings 
Reference 
Effect of 
bariatric surgery 
on gut-host 
metabolic cross 
talk 
1H-NMR based 
metabolic 
phenotyping of urine 
and faecal water 
samples, and 
pyrosequencing of 
faecal samples pre- 
and post- surgery  
 Increase in a number of 
metabolites post bariatric 
surgery, with several of 
those deriving from 
mammalian microbial co-
metabolism – 
demonstrated by an 
increase in diversity and 
complexity of signals in 
the aromatic region of the 
1H-NMR urinary spectra. 
 As metabolites derived 
from microbial 
(43) 
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fermentation increased, 
body weight decreased. 
Fingerprinting of 
the human gut 
phenotype 
LC-MS metabolic 
phenotyping of 
faecal samples and 
extracts taken from 
an in vitro human 
gastrointestinal tract 
model 
 Method enabled broad 
coverage of the faecal 
metabolome (9553 MS 
features detected). 
 Analysis of in vitro model 
extracts following addition 
of antibiotics, revealed 
metabolic changes linked 
to a shift in microbial 
diversity. 
(38) 
Metabolic 
activity of the 
gut microbiome 
in Ulcerative 
Colitis (UC) and 
Irritable Bowel 
Syndrome (IBS) 
1H-NMR metabolic 
phenotyping and 
PCR-denaturing 
gradient gel 
electrophoresis 
(PCR-DGGE) 
analysis of faecal 
samples from 
healthy and disease 
(UC and IBS) state 
patients 
 Differences in faecal 
metabolic profiles 
between healthy and 
disease states included 
glucose, amines, fatty 
acids and bile acids. 
 Correlation seen between 
gut microbiota 
composition and 
metabolite profiles. 
(44) 
Characterisation 
of an obese 
associated 
metabolic 
phenotype 
1H-NMR metabolic 
phenotyping of urine 
collected from 
obese patients 
compared to lean 
controls 
 Discrimination of urinary 
metabolic phenotypes 
based primarily on 
differences in hippuric 
acid, trigonelline, 2-
hydroxyisobutyrate and 
xanthine.  
 Following bariatric 
surgery, the obese 
(36) 
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associated metabolic 
phenotype is altered. 
 These results confirm that 
gut microbiome 
metabolism is strongly 
linked with human host 
metabolism. 
Microbial and 
metabolic 
molecular 
phenotyping to 
assess IBD risk 
LC-MS metabolic 
phenotyping and 
16S ribosomal RNA 
gene sequencing of 
faecal samples 
collected from 
families of paediatric 
IBD patients 
 Identification of two 
microbial and metabolic 
phenotypes in first degree 
relatives of paediatric IBD 
patients. 
 An IBD-associated 
molecular phenotype in 
healthy relatives suggests 
that shared genetic 
and/or environmental 
factors within families can 
be a pre-existing trait that 
precedes the acquisition 
of disease. 
(45) 
Table 1: Summary of some research studies conducted to date using untargeted 
metabolic phenotyping techniques, which further our understand of the gut 
microbiome-host metabolic interplay. 
 
Targeted Metabolic Phenotyping 
In “hypothesis driven” metabolic phenotyping studies (where targeted detection and 
quantification of specific metabolites of interest are required), MS is often the 
technology of choice over NMR. Despite improvements in instrument technology and 
both NMR and MS having the capability to conduct quantitative analyses, MS is still 
considered to be superior in terms of sensitivity, and most MS systems can be 
configured to capture specific molecules only, thereby providing selectivity (46).  
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Triple quadrupole MS instruments using Multiple Reaction Monitoring (MRM) are often 
used in targeted metabolic phenotyping studies, for enhanced sensitivity and 
selectivity. Here, the first and third quadrupoles of the MS instrument filters ions that 
have a different mass to charge ratio (m/z) than that of the desired ion of interest, 
resulting in targeted capture. Furthermore, the instrument can easily be coupled to 
chromatographic systems for prior separation of compounds of interest before MS 
detection, resulting in more focussed analysis. For example, GC coupled to MS would 
be ideally suited to capture volatile compounds, whereas polar compounds are better 
analysed by LC separation followed by MS detection. The addition of stable isotope 
chemical standards to biological study samples enables absolute quantification of 
metabolites. This approach is of growing interest and value, as the data can provide 
new reference range values.  
The development of targeted metabolic phenotyping methods to capture specific 
metabolites known to interact with the gut microbiome has deepened our 
understanding of the mechanisms leading to disease. In particular, this has shown 
promise in clinical research applications as it enables rapid measurement of several 
biomarkers in a single analytical run (rather than conducting several independent 
assays) from a single biological sample. Thus, reduces cost, saves time as well as 
sample volume requirement (often an issue in the case of studies where sample 
volume is limited). Furthermore, the sensitivity and specificity reported in studies 
conducted so far demonstrate its potential to possibly replace conventional lab-based 
clinical assays in the future (47, 48). A summary of recent research developments is 
given in Table 2. 
 
Study  Analytical Approach Key findings 
/Conclusion 
Reference 
Characterisation 
of metabolic 
signatures in 
paediatric IBD 
patients, using 
non-invasively 
Urinary bile acid 
quantification (LC-MS) 
and untargeted 
analysis conducted in 
parallel (GC-MS)  
 Identified a unique 
urinary signature of 
paediatric IBD 
 Differences include 
central energy 
metabolism, amino 
(49) 
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collected urine 
samples  
acids, bile acids and gut 
microbial metabolites 
Analysis of the 
faecal 
metabolome to 
identify volatile 
biomarkers in GI 
diseases, that 
are 
hypothesised to 
be produced by 
Clostridium 
difﬁcile and 
Campylobacter 
jejuni, during 
infections.  
Faecal volatile organic 
compound analysis 
(GC-MS).  
 Detected 297 faecal 
volatile compounds that 
discriminate between 
control and infected 
individuals’ samples 
 Of particular interest is 
the presence of 
butanoic acid in all 
groups except C. 
difficile samples 
 
(50) 
Assessment of 
the influence of 
indolic 
compounds 
(associated with 
commensal 
bacterial and 
plant 
metabolism) on 
human 
disorders of 
tyrosine 
metabolism 
Quantification of 
plasma indolic 
compounds alongside 
untargeted analysis 
(LC-MS).  
 
 Elevation of several 
indolic compounds in 
patient sera 
 Identified that the 
downstream indole 
metabolite, 
indolecarboxaldehyde, 
was produced 
exclusively by 
commensal gut 
bacteria. 
(51) 
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Development of 
a targeted 
method for 
quantification of 
short and 
medium chain 
fatty acids 
(MCFAs) in 
plasma, faeces 
and faecal 
fermentation 
samples 
SCFA and MCFA 
quantification (GC-
MS). 
 Newly developed 
method targets end 
products of gut 
microbiota fermentation 
(SCFAs) as well as 
markers of dietary 
triglyceride 
consumption (MCFAs) 
 Capture of multi-
compartment data aids 
in understanding 
biological mechanisms 
at a systems level. 
(52) 
Determination of 
compounds 
supporting the 
antifungal 
properties of 
lactic acid 
bacteria and 
propionibacteria 
Quantification of 
antifungal compounds 
in bacterial culture 
supernatants (LC-MS). 
 Identification of 
molecules produced by 
lactic acid bacteria and 
propionibacteria, that 
are responsible for their 
antifungal activity.  
 Good example of an 
analytical approach that 
may be applied to other 
strains of bacteria, to 
better understand 
functional activity.  
(53) 
Table 2: Studies conducted to understand gut microbiome-host metabolic interplay 
using targeted metabolic phenotyping approaches 
 
Data Integration 
Published literature has shown that data generated from metabolic phenotyping 
studies has the capacity to provide us with better understanding of gene-environment 
interactions (including the influence of the gut microbiota). However, studies have 
shown that this data can be enriched through fusion with other data such as clinical 
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markers, and those generated by other omics technologies (for example, genomics, 
proteomics, metagenomics etc.). Maximising information recovery enables deeper 
insight into the biological processes taking place in the entire system, and better 
understanding of disease mechanisms. For example, in a study by Elliott et al., 
metabolic data (acquired from urine samples using 1H-NMR spectroscopy and ion 
exchange chromatography) were integrated with anthropometric data from a large-
scale epidemiology study, with a view to better understanding which urinary 
metabolites contribute to BMI status (in order to characterise a metabolic signature of 
adiposity) (54). The statistical analysis identified metabolites significantly associated 
with BMI, implicating an extensive interconnected set of biochemical pathways and 
physiological processes, as well as involvement of the gut microbiota. As shown in 
Figure 1, when presented as an integrated metabolic reaction network of human 
adiposity (using the MetaboNetworks software program (55)), the fused data assisted 
in visualising metabolic paths linking the identified BMI-associated metabolites. In red 
boxes are metabolites positively correlated with BMI, and in blue boxes are 
metabolites negatively correlated. Of particular interest, is the mapping of gut 
microbial–related BMI markers (orange background) onto several pathways 
embedded in the host network. 
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Figure 1: Metabolic reaction network map identifying metabolites associated with 
BMI (red = higher BMI, blue = lower BMI) and their interconnectivities in the host 
system. Background shading visualises different types of metabolism (orange = gut 
microbial metabolism). Figure reproduced from Elliott et al. (54)) 
 
Another example of improved mechanistic understanding through data fusion is 
demonstrated by Zierer et al., who used a random forest approach to integrate 
epigenomics, transcriptomics, glycomics and metabolomics datasets together with 
clinical phenotypes, generating a model that identified distinct molecular markers of 
the aging process that might drive disease comorbidities (56). This study highlighted 
the benefits of data integration, as it not only confirmed associations that were 
identified previously (and modelled independently), but also uncovered potentially 
novel disease mechanisms. In another data driven approach by Noecker et al., a 
method for predicting community-wide metabolic turnover was applied to integrated 
metabolic phenotyping data and 16S community profiles, in order to calculate the 
biosynthetic and degradation potential of a given microbial community. A developed 
framework then compared predicted metabolic variation potential with actual 
measured concentrations, to assess whether bacterial composition can explain 
observed metabolic shifts, and identify key taxa and genes that were contributors to 
these shifts. The framework was applied to vaginal microbiome as well as gut 
microbiome datasets where 16S community profiling and metabolic phenotyping data 
were available. The results revealed that well-predicted metabolite variation generally 
resulted from disease-associated metabolism, and the authors identified several 
disease-enriched species that contributed to these predictions. Of note, was that the 
analysis also detected metabolites for which the predicted variation negatively 
correlated with the measured variation, suggesting environmental regulation of 
microbial metabolism (57). 
Summary Points  
 The gut microbiome still harbours unknown knowledge regarding its capacity to 
affect human health. This complex ecosystem produces several compounds 
during metabolism of nutrients and xenobiotics, and fermentation of dietary fibre, 
some of which interact with host metabolic processes, influencing host health.   
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 A clear understanding of these gut-host interactions are necessary for 
comprehensive understanding of disease aetiology. Metabolic phenotyping 
approaches provide such an opportunity, capturing targeted as well as novel 
markers of interest, providing insight into gut-host co-metabolic processes. 
 Taken together with microbiology and sequencing techniques, fusion of 
information provides functional assessment of the microbiome, unravelling the 
extent of the interplay between gut microbiome and mammalian host which 
should be exploited for therapeutic benefit. 
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